Oculis Holding AG (OCS) Stock Analysis

Company Overview

The market values Oculis Holding AG (OCS) at $675.78M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 60.

The 52-week range on file runs from $10.52 to $34.48. The most recent close on file for OCS is $12.17, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 15.68% above that 52-week low.

Financial Health

In fiscal 2025, Oculis Holding AG reported revenue of $0.00. The same year closed with a net loss of $98.96M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.7.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 576.11 times revenue. On price-to-sales that is 37.7 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.23. Annualized volatility over the trailing 5 years is 46.27%. Over the trailing twelve months the price has returned −29.08%. Across 5 years the annualized return works out at +4.71%.

Growth & Income

The record shows no dividend for OCS.

The strongest complete calendar year on file is 2024 at +51.38%; the weakest is 2022 at +4.23%. Of the 4 complete calendar years on file, 4 finished higher. So far in 2026 the price is −39.06%.